ArticleThe Lancet regional health. Western Pacific2024

Immunogenicity, safety, and reactogenicity of a half- versus full-dose BNT162b2 (Pfizer-BioNTech) booster following a two-dose ChAdOx1 nCoV-19, BBIBP-CorV, or Gam-COVID-Vac priming schedule in Mongolia: a randomised, controlled, non-inferiority trial.

Tsetsegsaikhan Batmunkh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.